CD8A and lymphoma: Administering thymosin α1 (Tα1) as part of sepsis treatment not only increases the number of CD4+ and CD8+ T cells and their functionality in individuals with lymphoma [210] but also stimulates DCs, augments natural killer (NK) cell activity, promotes macrophage phagocytosis, promotes HLA-DR in monocytes and inhibits the expression of PD-L1 [210, 211].